Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2023-04-16 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the authorization, amounts, types of financial products purchased, risk controls, and compliance with disclosure rules. The document is relatively short (2434 characters) and focuses on a specific financing activity related to the use of idle raised funds for cash management, including bank deposits and financial products. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best with a Capital/Financing Update (CAP) as it updates on the company's financing activities and capital management. Therefore, the appropriate classification is CAP with high confidence.
2023-04-16 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 first extraordinary general meeting of shareholders of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, agenda items, voting results, and legal opinions confirming the legality and validity of the meeting and its resolutions. The content focuses on shareholder voting results and corporate governance matters such as amendments to the articles of association and management rules. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. The document is not a report publication announcement since it contains substantive content about the meeting and voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4057 characters, which is sufficient to contain detailed voting results and resolutions. Confidence is high due to the clear presence of voting results and meeting resolutions.
2023-04-03 Chinese
北京德恒（杭州）律师事务所关于江西新赣江药业股份有限公司2023年第一次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedures of a company's 2023 first extraordinary general meeting (临时股东大会). It details the convening, attendance, agenda, and voting results of the shareholders' meeting. The document includes the voting results for various proposals and confirms the legality and validity of the meeting and its resolutions. This is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or a notice of dividend. The document is a formal legal opinion related to the shareholder meeting and its resolutions, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4745 characters, which is sufficient to contain detailed voting results and legal opinions, not just an announcement of a report publication. Therefore, the best classification is DVA.
2023-04-03 Chinese
使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of idle raised funds for cash management by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the amount of funds raised, their usage, storage, and the company's plan to invest idle funds in low-risk financial products. It includes opinions from independent directors, the supervisory board, and the sponsoring institution, and mentions that the matter requires approval at a shareholders' meeting. The document is a regulatory announcement about financing fund usage and management, not a full financial report or earnings release. It is relatively short (3460 characters) and does not contain financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP).
2023-03-15 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司使用募集资金置换预先已投入募投项目及已支付发行费用的自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from the sponsor (财通证券股份有限公司) regarding the use of raised funds by 江西新赣江药业股份有限公司 to replace self-raised funds previously invested in projects and issuance expenses. It references regulatory approvals, fundraising details, and compliance with listing rules on the Beijing Stock Exchange. The document includes detailed financial figures related to fundraising and fund usage, audit opinions, and board approvals. However, it is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement. It is a specialized verification or audit-related report concerning fundraising and fund usage compliance. This fits best under Audit Report / Information (AR), as it is a standalone audit/verification report related to fundraising and compliance, not a full annual or quarterly report, nor a general regulatory filing or announcement. Q1 2023
2023-03-15 Chinese
关于调整募集资金投资项目拟投入募集资金金额的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the amount of funds raised to be invested in specific projects by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the original and adjusted investment amounts, the approval process by the board and supervisory committee, and the opinions of the independent directors and the sponsoring institution. The document references the company's public issuance of shares and the use of raised funds but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about capital allocation related to fundraising, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is relatively short (2651 characters), but it contains substantive information about capital use adjustments rather than just announcing a report publication or certification, so it is not RPA or RNS.
2023-03-15 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.